ǂa ǂsingle-centre real-world study
Jurij Hanžel (Avtor), Tajda Božič (Avtor), Borut Štabuc (Avtor), Rado Janša (Avtor)

Povzetek

Background Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma. Patients and methods We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied. Results The median OS was 13.4 months (95% CI 8.2%18.6). Multivariable Cox%s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56%3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20%859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37%3.86; P = 0.002) to be associated with increased mortality. Conclusions Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.

Ključne besede

hepatocellular carcinoma;survival;sorafenib;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Organizacija: OI - Onkološki inštitut Ljubljana
Založnik: Association of Radiology and Oncology
UDK: 616-006
COBISS: 19073283 Povezava se bo odprla v novem oknu
ISSN: 1318-2099
Št. ogledov: 22
Št. prenosov: 17
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: hepatocelularni karcinom;preživetje;sorafenib;
Komentar vira: Soavtorji: Tajda Kosir Bozic, Borut Stabuc, Rado Jansa;
Strani: str. 233-236, XI
Letnik: ǂVol. ǂ54
Zvezek: ǂno. ǂ2
Čas izdaje: Jun. 2020
DOI: 10.2478/raon-2020-0027
ID: 24512692